Evidence map›Paper›PMID 35769841›Full record

ArticleJournal of research in pharmacy practice

Comparative Evaluation between the LaxaPlus Barij

Peiman Nasri, Shima Saeidi, Hosein Saneian, Fatemeh Famouri, Somayeh Sadeghi, Leila Mohammad Taghizadeh Kashani, Majid Khademian

Open access · goldAbstract read
In one paragraph

Article in Journal of research in pharmacy practice. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Peiman NasriMetabolic Liver Disease Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Shima SaeidiMetabolic Liver Disease Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Hosein SaneianMetabolic Liver Disease Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Fatemeh FamouriMetabolic Liver Disease Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Somayeh SadeghiAcquired Immunodeficiency Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Leila Mohammad Taghizadeh KashaniDepartment of Traditional Medicine, Medicinal Plants Research Center of Barij, Kashan, Iran.
Majid KhademianMetabolic Liver Disease Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Isfahan University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: This study aimed to compare the LaxaPlus Barij Methods: The present study is a randomized clinical trial. The study population included patients with functional constipation aged 2-15 years who were referred to the gastrointestinal clinic of Imam Hossein hospital in Isfahan in 2019. Patients were randomly assigned into two treatment groups. Data analysis was performed using SPSS software. The significance level in the present study is considered <0.05. Findings: Sixty children with functional constipation were selected based on the inclusion and exclusion criteria in this study. The present study results showed no significant difference between demographic characteristics, including age, weight, and gender of children with constipation in the two groups ( Conclusion: The present study results showed that both drugs effectively treat children with functional constipation. However, after 8 weeks of intervention, the frequency of bowel movements, pain intensity, and abdominal pain in the group LaxaPlus Barij

Indexed as

ChildconstipationLaxaPlus Barij®polyethylene glycol

Identifiers

PMID35769841
PMCPMC9235366
OpenAlexW4283738683

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.